PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Phenindione→

Phenindione PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
83-12-5
Molecular formula
C15H10O2
Molecular weight
222.24 g/mol
Drug class
Indandione oral anticoagulantvitamin K antagonist
Mechanism of action
Interferes with hepatic synthesis of functional vitamin K-dependent coagulation factors II, VII, IX and X, reducing the blood’s capacity to form thrombin and fibrin clots.
Indications / reported uses
  • Prevention and treatment of venous thrombosis and pulmonary embolism.
  • Prevention of systemic embolisation in selected patients with atrial fibrillation and rheumatic heart disease, and after insertion of prosthetic heart valves, under the product label and INR monitoring.

Sources: https://www.medicines.org.uk/emc/product/5677/smpc · https://www.medicines.org.uk/emc/product/5678/smpc

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Phenindione PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Phenindione Permitted Daily Exposure (PDE) report (the Phenindione PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Phenindione Occupational Exposure Limit (OEL) report (the Phenindione OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.